VolitionRX Stock

VolitionRX ROE

The Return on Equity (ROE) of VolitionRX (VNRX) as of Aug 3, 2026 is 108.27 %. In the previous year, Return on Equity (ROE) was 452.68 % — a change of -76.08% (lower).

ROE

108.27 %

YoY

-76.08%

Last updated:

In 2026, VolitionRX's return on equity (ROE) was 108.27 %, a -76.08% increase from the 452.68 % ROE in the previous year.

Access this data via the Eulerpool API

VolitionRX Stock analysis

What does VolitionRX do? VolitionRX Ltd was founded in 2010 with headquarters in Austin, Texas. It is a multinational life science company specializing in the discovery of cancer and other disease markers. The company's mission is to improve the quality of life for millions of people worldwide through the development of pain diagnostic systems. History VolitionRX began as a collaboration between scientists Professor Avraham Rasooly from the University of California and Professor David Kroll from North Carolina State University. The two professors were searching for a more effective diagnostic method for cancer and eventually co-founded VolitionRX in 2010. Initially, the company focused on developing diagnostic tests for stomach and colorectal cancer. Business model VolitionRX is a research-based company that specializes in the development of diagnostic and testing systems for cancer. The company works closely with leading cancer experts and scientific institutions to achieve groundbreaking research results. The goal is to develop innovative diagnostic methods that enable doctors to detect cancer faster and more effectively. Divisions VolitionRX is divided into three main areas: diagnostic tests, research and development, and partner and customer relations. Diagnostic tests VolitionRX offers a variety of diagnostic tests for cancer and other diseases. The tests are based on nucleosomics technology, which allows for analysis of cellular DNA. VolitionRX has developed various tests for colorectal cancer, lung cancer, pancreatic cancer, and other types of cancer, and is working on new tests for other conditions. Research and development VolitionRX continuously invests in research and development of new diagnostic methods for cancer and other diseases. The company collaborates closely with leading scientific institutions and cancer experts to develop innovative solutions for cancer diagnostics. Partner and customer relations VolitionRX works with a range of partners to distribute its diagnostic tests worldwide. The company has partnerships with various diagnostic laboratories and medical institutions to make its tests available to a wider target audience. Products VolitionRX offers a variety of products for the diagnosis of cancer and other diseases. These include: 1. NuQ blood tests for the diagnosis of colorectal cancer and other types of cancer. 2. Nucleosomics technology for analysis of cellular DNA for early cancer detection. 3. Software for data analysis from medical tests. Future prospects VolitionRX aims to further improve its technology for cancer diagnosis in order to save lives and improve the quality of life for people worldwide. The company's future prospects are promising as the demand for fast and effective cancer diagnostic methods continues to increase due to the rising number of cancer cases worldwide. VolitionRX is one of the most popular companies on Eulerpool.

ROE Details

Decoding VolitionRX's Return on Equity (ROE)

VolitionRX's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing VolitionRX's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

VolitionRX's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in VolitionRX’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about VolitionRX stock

Return on Equity (ROE) of VolitionRX is 108.27 % in 2026.

Return on Equity (ROE) of VolitionRX changed from 452.68 % to 108.27 %, representing a -76.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) VolitionRX since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s VolitionRX with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — VolitionRX

All Key Metrics — VolitionRX